X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
abridged index medicus (1) 1
aged (1) 1
alveolitis, extrinsic allergic - drug therapy (1) 1
alveolitis, extrinsic allergic - physiopathology (1) 1
aza, azathioprine (1) 1
azathioprine (1) 1
azathioprine - therapeutic use (1) 1
carbon monoxide (1) 1
care and treatment (1) 1
chp, chronic hypersensitivity pneumonitis (1) 1
chronic disease (1) 1
corticosteroid treatment (1) 1
critical care medicine (1) 1
cyclophosphamide (1) 1
diagnosis (1) 1
diffuse lung disease (1) 1
dlco, diffusion capacity of the lung for carbon monoxide (1) 1
dosage and administration (1) 1
female (1) 1
glucocorticoids - therapeutic use (1) 1
guidelines (1) 1
hp, hypersensitivity pneumonitis (1) 1
humans (1) 1
hypersensitivity pneumonitis (1) 1
idiopathic pulmonary-fibrosis (1) 1
ild, interstitial lung disease (1) 1
immunosuppressive agents - therapeutic use (1) 1
index medicus (1) 1
interstitial lung disease (1) 1
linear models (1) 1
lmm, linear mixed-effects model (1) 1
lung (1) 1
lung diseases (1) 1
male (1) 1
middle aged (1) 1
mmf, mycophenolate mofetil (1) 1
morbidity (1) 1
mycophenolate mofetil (1) 1
mycophenolic acid - therapeutic use (1) 1
pft, pulmonary function test (1) 1
pharmacology, experimental (1) 1
prednisone (1) 1
prednisone - therapeutic use (1) 1
pulmonary diffusing capacity (1) 1
pulmonary/respiratory (1) 1
recovery (1) 1
research (1) 1
respiratory system (1) 1
retrospective studies (1) 1
rituximab (1) 1
survival (1) 1
treatment outcome (1) 1
ubc, university of british columbia (1) 1
ucalgary, university of calgary (1) 1
ucsf, university of california, san francisco (1) 1
vital capacity (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Chest, ISSN 0012-3692, 2016, Volume 151, Issue 3, pp. 619 - 625
Background The treatment of chronic hypersensitivity pneumonitis (cHP) often includes systemic oral corticosteroids, but the optimal pharmacologic management... 
Pulmonary/Respiratory | azathioprine | mycophenolate mofetil | hypersensitivity pneumonitis | interstitial lung disease | SURVIVAL | LUNG | DIAGNOSIS | CYCLOPHOSPHAMIDE | GUIDELINES | RECOVERY | RESPIRATORY SYSTEM | RITUXIMAB | IDIOPATHIC PULMONARY-FIBROSIS | CORTICOSTEROID TREATMENT | CRITICAL CARE MEDICINE | Azathioprine - therapeutic use | Glucocorticoids - therapeutic use | Carbon Monoxide | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Alveolitis, Extrinsic Allergic - drug therapy | Linear Models | Male | Treatment Outcome | Alveolitis, Extrinsic Allergic - physiopathology | Vital Capacity | Pulmonary Diffusing Capacity | Mycophenolic Acid - therapeutic use | Female | Aged | Retrospective Studies | Chronic Disease | Prednisone - therapeutic use | Care and treatment | Pharmacology, Experimental | Hypersensitivity pneumonitis | Lung diseases | Prednisone | Dosage and administration | Research | Mycophenolate mofetil | Azathioprine | Morbidity | MMF, mycophenolate mofetil | UBC, University of British Columbia | Dlco, diffusion capacity of the lung for carbon monoxide | ILD, interstitial lung disease | PFT, pulmonary function test | AZA, azathioprine | LMM, linear mixed-effects model | UCSF, University of California, San Francisco | UCalgary, University of Calgary | cHP, chronic hypersensitivity pneumonitis | HP, hypersensitivity pneumonitis | Diffuse Lung Disease
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.